Logic-Gated infrastructure for adoptive immunotherapy

Unlocking the Undruggable Antigen Landscape.

GoCART builds recognition dimer CAR T cells for cancers that activate only when two antigens co-exist on the same cell, reducing off-target toxicity and making high-affinity binders against targets such as CD33, CD38 and CD56 clinically usable.

See the Platform View Timeline
Scroll for the full story

Why Now

A lot of critical antigens are still unusable.

The challenge lies in identifying binders that can be deployed safely. The most effective antigen targets prove lethal when engaged through single-input logic. GoCART is built to safely unlock that undruggable antigen layer in MM and AML.

MM

Initial focus with a path to safer high-affinity targeting.

AML

Priority indication where target overlap creates a severe toxicity constraint.

CD56 AND-Gated Targeting

Conventional single-input CAR-T therapies cannot safely target CD56 due to systemic expression and severe toxicity risk. GoCART unlocks CD56 through combinatorial AND-gate logic, pairing it with CD33 in AML and CD38 in Multiple Myeloma. By requiring dual-antigen engagement, our platform transforms a powerful but unsafe target into a precision-controlled therapeutic entry point.

Current Constraint

Conventional CAR T cells work best when one clean antigen exists. Targets overlap with healthy tissue and become unusable at therapeutic affinity.

Failure Mode

Single-input activation triggers on non-malignant cells at physiologic antigen levels, driving off-target toxicity and systemic safety failure.

Strategic Need

The field needs an architecture that keeps high-affinity binding intact while enforcing strict combinatorial specificity, not a weaker compromise.

Sources: FDA AUCATZYL; FDA BREYANZI; FDA KYMRIAH; FDA TECARTUS; FDA YESCARTA; FDA ABECMA; FDA CARVYKTI.

Recognition Dimer Platform

True AND-gate logic for previously undruggable antigens.

GoCART's architecture requires simultaneous engagement of two antigens before activation, preserving high-affinity binding while enforcing spatial coincidence and reducing systemic toxicity.

GoCART recognition dimer platform diagram

AND Logic, Not Approximation

Activation is gated by dual-antigen recognition on the same cell, eliminating activity from isolated low-level expression on healthy cells.

High-Affinity Binder Unlock

Binders that would otherwise be clinically unusable due to lethal toxicity become safe when their activity is gated by a second antigen requirement.

Program Expansion Engine

The modular design supports rapid extension into new antigen pairs without rebuilding the core logic layer.

Sources: 1. Hamieh et al. Cancer Discov (2023); 2. Tousley et al. Nature (2023).

Venture Execution

Current Phase: Seed Validation

We are executing a $150k Seed Round to complete our in-vitro proof of concept. This phase validates our proprietary binder interface and finalizes the in-silico pipeline through the University of Cádiz.

The Institutional Inflexion

Completing this phase de-risks the platform architecture. This triggers a larger institutional round to fund in-vivo preclinical R&D. This next stage focuses on safety and efficacy in animal models, transitioning GoCART from laboratory validation to a clinical-grade asset.

Execution Discipline

The financing sequence moves GoCART from laboratory validation toward a clinical-grade asset by aligning capital deployment with each technical de-risking milestone.

Leadership

Operators across translational science, platform engineering, and scale-up.

Henry Erdlei

Henry Erdlei, MD

Chief Executive Officer

Doctoral research in translational tumor immunology at Max Delbruck Center (MDC Berlin) and InIBiCA Cadiz, with hands-on CAR-T design, T-cell engineering, antigen recognition logic, and medical training at Charite spanning oncology, CAR-T toxicity, CRS, and clinical execution.

Arailym Myrzagaliyeva

Arailym Myrzagaliyeva

Head of Scientific Outreach

Background in cancer biology and molecular biotechnology, with experience leading scientific outreach and partnerships through iGEM NU-Kazakhstan, collaborating with Roche, AstraZeneca, Pfizer, and academic institutions, and building public health and education initiatives centered on scientific communication and stakeholder engagement.

Chase Blakeley

Chase Blakeley

Chief Operating Officer

Former Oracle and Tesla business development specialist with a record of high-performance execution and strategic partnerships in high-tech environments, managing the operational bridge between GoCART's technical milestones and institutional capital requirements.

Roadmap

From in-vitro validation to regulatory approval.

2026

In vitro proof-of-concept studies in AML and Multiple Myeloma cell lines to validate target-specific activation, cytokine release control, and tumor cell killing at low antigen densities. This stage benchmarks the logic-gated design against conventional CAR-T and establishes the foundation for IND-enabling in vivo work. Budget: $150K over 12 months.

2027-2028

IND-enabling work and GMP scaling, including final lead selection, GLP toxicology, transition to GMP manufacturing, and preparation for Phase I first-in-human work in RRMM and AML. By late 2028, the target is to initiate first-in-human studies while leveraging accelerated Orphan Drug pathways. Budget: $3M-$5M over 18-24 months.

2033

First regulatory approval target following successful Phase I/II readouts and BLA submission, with the goal of establishing the ABC Trimer as the new standard for safe, high-precision cell therapy.

Strategic & Technical FAQ

Key diligence questions, expanded on hover.

Why lead with Multiple Myeloma (MM) in a "crowded" market?

Incumbents rely heavily on BCMA, which remains exposed to downregulation and immune escape. GoCART targets CD56 and CD38 to create a more durable entry point in MM, while keeping the same platform transferable to AML.

How does GoCART's toxicity management differ from current solutions without an "AND" gate?

Standard approaches often reduce binder affinity to keep healthy tissue activation at bearable levels, which weakens potency. Our extracellular logic gate preserves high-affinity binders while enforcing activation only when both antigens are present on the same cell.

How does adding a soluble binder layer affect the development timeline?

The complexity is offset by existing infrastructure. The lab already runs vector design, CAR expression, and functional testing for related systems, so the FACS-FRET assay is the main new experimental layer rather than a full rebuild of the workflow.

What is the manufacturing strategy for clinical scale?

GoCART is being built as an asset-light organization. We use established production partners for lentiviral vector manufacturing and outsource antibody-domain design and testing to specialized partners, which reduces early capex while preserving flexibility across new combinations.

Is $150k sufficient to reach a critical milestone?

Yes. The $150k Seed Round is scoped to hit a defined inflection point: in-vitro proof of concept, completion of the in-silico pipeline, validation of the binder-binder interface, and initial patent filings that de-risk the next institutional raise.

What is the primary competitive moat?

Most competitors are optimizing binders for the same narrow set of targets. GoCART is building the logic-gated operating system that makes undruggable antigens usable, positioning the platform as enabling infrastructure rather than a single-asset bet.